Objective-To define the contribution of vascular smooth muscle cell (SMC)-derived factors to macrophage phenotypic modulation in the setting of vascular injury. Approach and Results-By flow cytometry, macrophages (M4) were the predominant myeloid cell type recruited to wireinjured femoral arteries, in mouse, compared with neutrophils or eosinophils. Recruited macrophages from injured vessels exhibited a distinct expression profile relative to circulating mononuclear cells (peripheral blood monocytes; increased: interleukin-6, interleukin-10, interleukin-12b, CC chemokine receptor [CCR]3, CCR7, tumor necrosis factor-α, inducible nitric oxide synthase, arginase 1; decreased: interleukin-12a, matrix metalloproteinase [MMP]9). This phenotype was recapitulated in vitro by maturing rat bone marrow cells in the presence of macrophage-colony stimulating factor and 20% conditioned media from cultured rat SMC (sMφ) compared with maturation in macrophage-colony stimulating factor alone (M0). Recombinant transforming growth factor (TGF)-β1 recapitulated the effect of SMC conditioned media. Macrophage maturation studies performed in the presence of a pan-TGF-β neutralizing antibody, a TGF-β receptor inhibitor, or conditioned media from TGF-β-depleted SMCs confirmed that the SMC-derived factor responsible for macrophage activation was TGF-β. Finally, the effect of SMC-mediated macrophage activation on SMC biology was assessed. SMCs cocultured with sMφ exhibited increased rates of proliferation relative to SMCs cultured alone or with M0 macrophages. 
N eointimal hyperplasia is known to occur in the context of atherosclerosis or after percutaneous interventions, bypass grafting, or transplant. Despite the implementation of drug-eluting stents, luminal narrowing because of restenosis remains a significant clinical problem. 1 A more complete understanding of the pathogenesis of neointimal hyperplasia is required to design more precisely targeted therapies that will allow for complete re-endothelialization of revascularized or grafted vessels and vessel repair to improve outcomes.
Neointimal lesions have been shown to be largely composed of activated or dedifferentiated vascular smooth muscle cells (SMCs) that migrate from the tunica media to the developing neointima. 2, 3 Activation of resident SMCs is a complex, multi-faceted process that promotes a transition to a highly proliferative, inflammatory phenotype characterized by downregulation of SM contractile genes and increased production of multiple growth factors, cytokines, and chemokines. [4] [5] [6] [7] Many of these factors participate in neointima formation through direct effects on SMCs combined with recruitment of inflammatory cells, which sustains lesion progression. Because SMCs are critical in initiating and promoting neointima formation, targeting SMCs is a potent strategy to inhibit progression of vascular disease. However, simply focusing on blocking SMC proliferation is likely an ineffective means to prevent disease because these therapies inhibit proliferation of other cells (ie, endothelial cells) that are required for vessel recovery. Preventing vascular inflammation is an equally important approach to limit restenosis because this process also plays a central role in intimal growth. Several studies have demonstrated a critical role for recruited macrophages in the progression of neointimal hyperplasia. [8] [9] [10] [11] [12] [13] [14] For example, clodronate depletion of macrophages has been shown to reduce injury-induced neointima formation in both the mouse 15 and rat. 13 However, the mechanisms underlying how macrophages specifically cross talk with SMC, and vice versa, to induce or perpetuate SMC activation and neointimal hyperplasia are not well understood.
Macrophages are highly plastic cells, which undergo phenotypic modulation in response to signals from the microenvironment. Macrophage phenotypic modulation, or polarization, is typically described as either lipopolysaccharide/interferon-γ-mediated classical (M1) activation or interleukin-4 (IL-4)/ IL-10-mediated alternative (M2) activation. 16, 17 Modulation of macrophage phenotype in the vasculature has largely been studied in the context of atherosclerosis, where these cells have been found to exhibit a spectrum of phenotypes. [18] [19] [20] [21] Because macrophages have been identified as the predominant inflammatory cell infiltrating injured vessels, the objectives of this study were to characterize the phenotype of macrophages recruited to neointimal lesions in vivo, to determine how signals from SMCs contribute to this macrophage phenotype, and to understand whether macrophages modulated by SMCs gain the ability to signal back to SMCs to promote or maintain SMC activation. Herein, we describe identification of SMC-derived transforming growth factor (TGF)-β as a critical mediator of SMC-induced macrophage phenotypic modulation in an in vitro system designed to recapitulate monocyte-to-macrophage modulation as would occur after macrophage recruitment to regions of vascular injury.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Macrophages Recruited to Injured Vessels Are Phenotypically Distinct From Peripheral Blood Monocyte Precursors
Our group, 9 and others, 3, 12 have shown increased recruitment of bone marrow-derived macrophages to the arterial wall after endothelial denudation-mediated arterial injury. Flow cytometry was used to verify enhanced presence of macrophages in the setting of vascular injury (gating strategy: Figure IA in the online-only Data Supplement) at 15 days postinjury, when macrophage accumulation was observed to be maximal, 12 and when neutrophil recruitment is expected to have abated. 22 We found that in injured femoral arteries, relative to contralateral control femoral arteries or aortas from injured animals and femoral arteries or aortas from naïve animals, macrophages made up a significantly larger percentage of total cells than did neutrophils, eosinophils, or dendritic cells ( Figure IB -IF in the online-only Data Supplement), and eosinophil and neutrophil recruitment were not increased at this time point after injury. We sought to determine whether these recruited macrophages are phenotypically distinct from peripheral blood monocyte (PBMC) precursor monocytes. To compare neointima-associated macrophages versus circulating monocyte controls, CD11b+ cells were isolated from injured femoral arteries or histopaque-separated buffy coats by positive selection using anti-CD11b antibody-conjugated magnetic beads. Positively selected cells stained for F4/80, indicating that they were largely monocytes/macrophages, whereas nonselected cells stained positive only for SM α-actin, representing SMCs, or were negative for both F4/80 and SM α-actin, indicating other cell types ( Figure  IIA in the online-only Data Supplement). CD11b positive selection resulted in 80% monocyte/macrophages from either PBMCs or injured femoral arteries. Injured artery isolations contained similar percentages of eosinophils and neutrophils and slightly more dendritic cells than did PBMC isolations ( Figure IIB in the online-only Data Supplement). Expression of a panel of genes was assessed in CD11b positive cell isolates by real time quantitative polymerase chain reaction. We focused on genes that have been shown to be upregulated in bone marrow cell-derived rich regions of neointimae, 3 as well as on genes that have been suggested to be upregulated in inflammatory mouse, rat, and human macrophages. 23 Several genes (IL-6, CC chemokine receptor [CCR]3, CCR7, IL-10, IL-12b, and tumor necrosis factor [TNF]-α) were upregulated in CD11b+ cells from injured vessels relative to CD11b+ PBMCs (Figure 1 ). In contrast, expression of IL-12a and matrix metalloproteinase (MMP)9 was repressed in CD11b+ cells from injured vessels relative to PBMC controls ( Figure 1 ). In addition to this 9-gene panel, we assessed expression of inducible nitric oxide synthase (iNOS) and arginase 1 (Arg I), markers of M1 and alternatively activated M2 macrophages, respectively. INOS and Arg I expression was higher in CD11b+ cells from injured arteries relative to controls (Figure 1 ). Together, these data suggest that in addition to increased recruitment on vascular injury, monocytes 
Phenotypic Modulation of MΦ by Conditioned Media From SMCs
We hypothesized that the signals driving macrophage phenotypic modulation are derived, at least in part, from SMCs. We, therefore, developed an in vitro system to determine whether maturation of bone marrow-derived monocytes in the presence of factors secreted by SMCs results in phenotypic modulation resembling lesion-associated macrophages. Rat bone marrow cells were matured, as previously described, 24 with recombinant mouse macrophage-colony stimulating factor in the presence (sMφ) or absence (M0) of conditioned media (CM) obtained from rat aortic SMCs. Bone marrow cells were exposed to CM from SMCs at day 2 of culture and harvested at day 7 for analysis. As shown in Figure 2A , exposure of bone marrow cells to SMC-derived factors early in maturation resulted in a pronounced change in morphology. These cells were more rounded with shorter processes, whereas M0 cells were more elongated with ≥2 extended processes. The expression of the macrophage marker CD68 was assessed in these cells by immunofluorescence. SMφ express CD68 (rat ED1) at similar levels as M0 macrophages, indicating these cells retained a macrophage phenotype ( Figure IIC in the online-only Data Supplement). Quantitative polymerase chain reaction analysis of the previously described in vivo 9-gene panel in sMφ, relative to M0 controls, closely recapitulated the signature found in macrophages isolated from injured vessels ( Figure 2B ). Upregulation or downregulation of chemokine (cc motif) ligand (CCL)5, IL-6, IL-10, IL-12b, CCR3, CCR7, and MMP9 was concordant between this in vitro system and in vivo injury model. Luminex multiplex bead assays were used to verify modulation of cytokines at the protein level. Transcriptional regulation of IL-10, CCL5, and TNF-α correlated with protein production ( Figure 2D ), whereas transcriptional regulation of IL-6 and IL-12p70 was undetectable by this method (not shown). Expression of the M1/M2 markers iNOS and Arg I was assessed by quantitative polymerase chain reaction in these cells. Similar to macrophages recruited to injured vessels, sMφ expressed high levels of iNOS but low levels of Arg I relative to M0 ( Figure 2C ). These data suggest that maturation of bone marrow-derived monocytes in the presence of factors derived from SMC recapitulates many of the features of neointimaassociated macrophages observed in vascular lesions in vivo. This in vitro model system establishes a novel framework for studying macrophage maturation and function that is B and C, Total RNA was isolated, and quantitative polymerase chain reaction was conducted for the indicated mRNAs. Shown are mRNA copy number normalized to GAPDH (means±SE; n=6 independent experiments). D, Conditioned media was collected from M0 and sMφ at day 9, 48 hours after replacing media with culture medium containing 0.1% fetal bovine serum, concentrated, and assayed for interleukin-10 (IL-10), CCL5, and tumor necrosis factor (TNF)-α protein levels. Shown are means±SE; n=7 independent experiments (*P<0.05 vs M0). Arg 1 indicates arginase 1; iNOS, inducible nitric oxide synthase; M0, macrophage matured in the absence of SMC conditioned medium; and sMφ, macrophage matured in the presence of SMC conditioned medium.
specifically relevant to injury-induced neointima formation. Furthermore, this system establishes a novel in vitro platform for understanding intercellular cross talk between the SMCs and recruited macrophages.
Characterization of the Factors Produced by SMCs, Which Mediates sMΦ Induction
To identify potential factors secreted by SMCs responsible for macrophage phenotypic modulation, we used several techniques to test physical properties of the factors. SMC CM was heat-treated in a boiling bath for 10 minutes to denature heat-labile factors. The macrophage-modulating activity of SMC CM was enhanced by heat treatment ( Figure , confirming that the factors are polypeptide. Size fractionation was performed with 100 kDa cut off centrifugal filters and revealed that the macrophage-activating factor partitions to the >100 kDa fraction in the native CM ( Figure IIID in the online-only Data Supplement). To determine whether heat-dependent activation of the factors is because of dissociation of an inhibitor, or inhibitory complex, size exclusion studies were performed after heat treatment. These studies showed that the macrophage-modulating activity partitions to the <100 kDa fraction after heat treatment ( Figure IIID in the online-only Data Supplement). Together these data suggest that a peptide-based factor is secreted from SMCs in a large (>100 kDa), less active complex, and activity is enhanced by heat treatment through a mechanism, resulting in reduction of the molecular weight of the active component.
Exposure of Bone Marrow-Derived Cells to TGF-β Leads to Induction of the sMΦ Phenotype
Latent, complex-bound TGF-β is secreted into the extracellular space in the vasculature and undergoes activation on mechanical injury. 25 Latent TGF-β is also known to be activated in vitro by heat and acidic conditions. 26 Activation is associated with a change in molecular weight, similar to what we have observed with CM. Furthermore, blocking TGF-β signaling in in vivo vascular injury models has been shown to inhibit neointima formation. [27] [28] [29] [30] [31] [32] [33] Because the macrophage-modulating activity in SMC CM appeared characteristic of TGF-β, we next tested the effect of recombinant human (rh) TGF-β on macrophage phenotype. Maturation of macrophages in the presence of rhTGF-β1 recapitulated the morphological modulation observed with SMC CM ( Figure 3A ) and recapitulated the expression signature of the previously described 9-gene quantitative polymerase chain reaction panel observed in sMφ ( Figure 3B , left). Similar to SMC CM, iNOS and Arg I showed increased and decreased expression, respectively, in macrophages matured with rhTGF-β ( Figure 3B, right) . Increased IL-10 and CCL5 and decreased TNF-α protein levels were verified by Luminex assay ( Figure 3C ).
SMC-Derived TGF-β Promotes Macrophage Modulation Observed in In Vitro Maturation Studies
Bone marrow cells stimulated with SMC CM showed increased phosphorylation of SMAD2, which was detectable by 30 minutes, and remained elevated for ≥90 minutes ( Figure 4A ). The level of stimulation was comparable to that observed with rhTGF-β, although somewhat delayed, indicating that canonical TGF-β signaling occurs in macrophages in response to SMC CM. The delayed stimulation of SMAD2 suggested that macrophages activate SMC-derived latent TGF-β1. Latent TGF-β1 was detectable in SMC CM at an average concentration of 350 pg/mL (Figure IVA in the online-only Data Supplement). As shown in Figure 4A , activation of SMAD2 in response to SMC CM was completely inhibited by a specific TGF-β receptor 1 (TBR1) inhibitor, SB431542 (10 μmol/L).
To confirm that TGF-β is a critical factor in SMC CM responsible for inducing macrophage phenotypic modulation, we used several complementary strategies. Pharmacological inhibition of TGF-β signaling with SB43152 resulted in blockade of the morphological change induced by SMC CM ( Figure 4B ). This inhibitor also abolished SMC CM-induced increases in gene expression of IL-6, CCL5, IL-10, IL-12a, IL-12b, CCR3, and CCR7, as well as reversed the decreases in TNF-α and MMP9 expression ( Figure 4C ). Finally the receptor inhibitor reversed the expression of macrophage phenotypic markers, decreasing expression of iNOS and increasing expression of Arg I ( Figure 4C ). Inhibition of cytokine up/downregulation by TBR1 inhibition was confirmed by Luminex assay ( Figure IVB in the online-only Data Supplement). To confirm these findings, a pan-specific anti-TGF-β neutralizing antibody was used to inhibit SMC CM-mediated TGF-β signaling to macrophages during maturation. Compared with vehicle control, neutralization of TGF-β resulted in blockade of the morphological change ( Figure 4D ) and abolished altered gene expression of IL-6, CCL5, IL-10, IL-12a, IL-12b, CCR3, CCR7, TNF-α, MMP9, iNOS, and Arg I ( Figure 4E ) induced by SMC CM. These effects were specific for anti-TGF-β and were not observed with antibodies against platelet-derived growth factor-BB (PDGF-BB) or stromal cell-derived factor (SDF-1α) ( Figure IVC and IVD in the online-only Data Supplement).
TGF-β neutralizing antibody and TBR1 inhibition studies cannot rule out that an unknown factor produced by SMC triggers TGF-β release from macrophages, which then mediates these changes in an autocrine manner. Therefore, TGF-β was silenced in SMCs using small interfering RNA and media conditioned by control or TGF-β-silenced SMCs. TGF-β was decreased by >80% in cells receiving the TGF-β-specific small interfering RNA compared with nontargeting control small interfering RNA-treated SMCs ( Figure VA in the online-only Data Supplement). Compared with maturation of macrophages in the presence of SMC CM from nontargeting small interfering RNA-transfected SMC, maturation of macrophages with TGF-β-silenced SMC CM showed a ≈50% decrease in macrophage phenotypic modulation ( Figure VB and VC in the online-only Data Supplement). Taken together, these data suggest a critical role for SMC-derived TGF-β in the maturation of a phenotypically distinct macrophage population, which exhibits a hybrid M1/M2 activation state and may be specifically primed to contribute to SMC activation. 
Phenotypic Modulation of Macrophages by SMC-Derived TGF-β Is p38 Mitogen-Activated Protein Kinase Dependent
To define mechanisms mediating the effects of SMC-derived factors on Mφ phenotype, we assessed the contribution of downstream signaling pathways using a pharmacological strategy. We assayed a panel of small molecule inhibitors of signaling pathways likely to be involved in altered maturation. Mφ were exposed to BAY 11-7082, an inhibitor of nuclear factor-κB signaling, LY-294002, a phosphoinositide 3-kinase inhibitor, SB203580, a p38 MAP kinase inhibitor, PD-98059, a MEK-1/2 (mitogen-activated protein kinase kinase) inhibitor, and sulindac sulfide, a cyclooxygenase inhibitor throughout the course of maturation with SMC CM. Inhibition of p38 activity with SB203580 was the only condition exerting an inhibitory effect on macrophage morphological modulation by SMC CM ( Figure VIA in the online-only Data Supplement). In addition, p38 inhibition abrogated transcriptional changes induced in the previously described panel of genes (IL-6, CCL5, CCR3, CCR7, IL-10, IL-12a, IL-12b, TNF-α, MMP9, iNOS; no significant differences in Arg I; Figure 5A and Figure VIB in the online-only Data Supplement). Exposure to SB205380 also blocked the morphological and transcriptional changes induced by recombinant TGF-β ( Figure 5B and 5C) and inhibited upregulation and downregulation of iNOS and Arg I, respectively, mediated by TGF-β ( Figure 5D ). These data suggest that the ability of SMC-derived factors to induce phenotypic modulation of macrophages is dependent on p38 mitogen-activated protein kinase signaling.
Macrophages Matured in the Presence of SMCDerived TGF-β Exhibit Cross Talk With SMC
To begin to define how the phenotypic modulation of macrophages by SMC-derived TGF-β influences macrophage cross talk with SMCs, we performed in vitro coculture studies. After 7 days of maturation, M0 cells or sMφ were placed in Boyden chamber inserts and cocultured with 48 hours serum-restricted SMCs for 48 hours. We observed an increase in cell proliferation, as assessed by SMC DNA synthesis by bromodeoxyuridine incorporation, at 48 hours as compared with SMC alone or in coculture with M0 macrophages ( Figure 6A ). We examined expression of several cytokines previously shown to be upregulated in activated SMC. 9 Exposure of SMC to either M0 or sMφ macrophages induced expression of monocyte chemoattractant protein-1 (MCP-1), keratinocyte chemoattractant, and SDF-1α in SMC after 48 hours of coculture. However, there was no significant difference in the degree of induction ( Figure 6B ).
Discussion
Progression of vascular remodeling in response to vascular injury involves complex interactions between vascular cells and recruited inflammatory cells. Inflammatory cells, including circulating monocytes, are recruited to the site of injury where they undergo differentiation into macrophages. In human atherectomy samples, presence and numbers of macrophages predict development of restenosis with high significance. 34 Macrophages have been shown to contribute to pathogenesis of restenosis through secretion of growth factors, cytokines, and chemokines, which induce SMC and endothelial cell proliferation, as well as contribute to SMC activation. Neointimal lesion macrophages additionally contribute to the developing neointima by secreting matrix-remodeling enzymes (eg, MMPs) that facilitate development of fibrosis. 4 Macrophages exhibit remarkable phenotypic plasticity in response to signals from the local tissue microenvironment. The phenotype of macrophages in an injured vessel will depend on both the lineage commitment and environmental signals generated through interactions with other cell types in the lesion, including SMCs. 20 The goal of this study was to define characteristics of macrophages in the developing neointima that are distinct from other immature/circulating monocytes and to define the role SMCs plays in influencing this macrophage phenotype. Understanding the signals critical for macrophage phenotypic modulation may shed light on novel therapeutic strategies to limit SMC proliferation and extracellular matrix deposition while allowing for re-endothelialization and reduction of thrombotic events. Index) . B, Rat BMC were matured and replated with serum-restricted SMC as described in A for 48 hours. Total RNA was isolated from SMC and analyzed by quantitative polymerase chain reaction for the indicated mRNAs. Shown are mRNA fold change in copy number, relative to SMC, normalized to GAPDH. Shown are means±SE; n=6 independent experiments (*P<0.05 vs untreated SMC). CC'd indicates cocultured; M0, macrophage matured in the absence of SMC conditioned medium; and sMφ, macrophage matured in the presence of SMC conditioned medium.
Using flow cytometry, we were able to demonstrate increased recruitment/retention of monocyte/macrophages to injured vessels and define an expression signature that distinguishes macrophages derived from injured vessels from precursor monocytes. These macrophages manifest several features of classically activated M1-like macrophages, 35 although there were some noted dissimilarities (eg, decreased TNFα and increased arginase I expression), possibly suggesting a complex activation state. We hypothesized that factors produced by SMC were critical in promoting this injury-associated phenotype. Using an in vitro system, we were able to demonstrate that changes in most of the genes in the signature found in macrophages from injured vessels were recapitulated in bone marrow-derived macrophages exposed to factors from SMC (sMφ) compared with macrophages not exposed to these factors (M0). Discordant gene expression between in vitro versus in vivo experiments could potentially be explained by increased dendritic cell numbers in injured vessels versus circulating mononuclear cells in in vivo studies. Furthermore, using several strategies, we identified TGF-β1 as the critical SMC-derived factor responsible for inducing this macrophage phenotype. The Table summarizes the changes in gene expression observed in vivo compared with in vitro studies and in the setting of inhibiting TGF-β signaling in vitro.
TGF-β has been implicated as a critical mediator of the neointimal hyperplastic response after vascular denudation injury. Mechanical injury results in the upregulation of TGF-β expression by medial SMC and the activation of latent matrixbound TGF-β. The restenotic response after vascular injury is enhanced with TGF-β infusion or overexpression, whereas the response is suppressed when TGF-β is blocked or neutralized. In addition, downstream TGF-β signaling (SMAD2/3) has been shown to be enhanced in injured vessels. 36 However, TGF-β is known to have an antiproliferative and prodifferentiating effect on SMC (regardless of SMC developmental origin) by cooperating with serum response factor-myocardin complexes to induce smooth muscle contractile protein expression. 37, 38 These data argue that the mechanism by which TGF-β promotes neointimal hyperplasia is not mediated through medial SMCs but rather through another cell population present in the developing neointima that then signals to SMCs in a proproliferative manor. Our data suggest that this involves phenotypic modulation of recruited monocyte/macrophages by SMC-derived TGF-β, as well as bidirectional cross talk between these modulated macrophages and resident medial SMCs, which indirectly promotes SMC proliferation.
The effect of TGF-β on immature circulating monocytes is considered proactivating because of high expression of TGF-β receptors on immature monocytes. TGF-β has less of an effect on tissue macrophages because of decreased receptor expression. For example, picomolar concentrations of TGF-β have been shown to induce TNF-α and IL-6 expression in human monocytes. Interestingly, this increase in TNF-α expression has not been observed in the mouse and, similarly, we did not observe increased TNF-α in vivo or in vitro. However, most studies that suggest that TGF-β is a macrophage inhibitory factor have been performed in the context of thioglycollate elicitation or lipopolysaccharide or phorbol ester stimulation. These studies, therefore, may not reflect the effect of TGF-β on macrophage phenotype in the absence of potent macrophage-activating agents. [39] [40] [41] Additional studies will be required to ascertain whether deficiency in TGF-β signaling, specifically in myeloid cells, results in a net exacerbation or amelioration of neointimal hyperplasia in response to arterial injury.
Although systemic inhibition of TGF-β signaling in vivo is feasible, interpreting the results of those studies may be problematic. Recent studies demonstrated pleiotropic effects of TGF-β in response to vascular injury. 36 Recent work by Wan et al 31 demonstrated that systemic blockade of TGF-β Gene expression data from in vivo injury study (column 2; Figure 1 ) compared with gene expression data from select in vitro macrophage maturation experiments. Column 3, Figure 2 ; column 4, Figure 3 ; column 5, Figure 4 ; and column 6, Figure V in the onlineonly Data Supplement. Data expressed as mean (copy no./GAPDH relative [Rel.] to indicated condition)±SEM. CM indicates conditioned media; M0, macrophage matured in the absence of smooth muscle cell conditioned medium; NA, not assessed; PBMC, peripheral blood mononuclear cell; rhTGF, recombinant human transforming growth factor; siTGF, silencing of TGF-β; sMφ, macrophage matured in the presence of smooth muscle cell conditioned medium; SMC, smooth muscle cell; and TBRI, transforming growth factor-β receptor 1.
signaling, either using an neutralizing inhibitor or a pharmacological inhibitor of TBR1, inhibited the recruitment of mesenchymal stem cells to the site of injury. These authors also demonstrated that blocking TGF-β signaling also inhibited the increase in MCP-1 observed in response to injury, which would lead to an overall macrophage recruitment defect. We propose that TGF-β does not mediate recruitment of inflammatory cells directly to injured vessels but rather promotes a phenotypic change in cells once they are recruited (eg, in response to increased production of chemokines known to recruit inflammatory cells such as MCP-1). Thus, it will be necessary to inhibit TGF-β signaling selectively in macrophages. We are, therefore, currently generating mice with targeted deletion of the TBRII in myeloid lineages for future studies to address this question in an in vivo setting of vascular injury. Recent findings from Pang et al 42 showed that myeloid-specific TBRII deficiency in TGF-β-driven disease results in abrogation of macrophage modulation (decreased iNOS, Arg I, IL-6, IL-10, and IL-12 and increased TNF-α and MMP9). This study found that inhibition of myeloidspecific TGF-β signaling was sufficient to inhibit tumor metastasis, suggesting that our in vivo expression signature is largely TGF-β dependent and that myeloid-specific inhibition of TGF-β signaling, on macrophage recruitment to lesions, would be expected to significantly reduce neointimal hyperplasia after injury.
Our data implicate p38 MAP kinase as a critical signaling pathway for formation of sMφs. A pharmacological inhibitor of this pathway blocked both the morphological change and the changes in gene expression induced by SMC CM or rhTGF-β. However, we have not been able to detect increases in active (phospho) p38 in response to either stimulus (not shown). In fact, steady state levels of phospho-p38 in sMφ are not different from M0 macrophages at any of the time points examined. It is possible that a transient p38 activation occurs during the 5-day time course required for sMφ formation, which we have failed to detect. Alternatively, constitutive p38 activity in these cells may represent a necessary but insufficient signal for sMφ formation. For instance, signaling by macrophage-colony stimulating factor may prime macrophages to respond to TGF-β signaling, with both pathways collaborating to produce the sMφ phenotype. The requirement for p38 activity in sMφ formation may partially explain the efficacy of p38 inhibitors for reducing wire-induced stenosis. 43 Our data indicate that sMφ can reciprocally signal back to SMC. SMC in coculture with sMφ had increased rates of proliferation compared with coculture with M0, suggesting production of a sMφ-specific soluble factor that stimulates SMC proliferation. We hypothesized that such a factor might be PDGF-BB; however, PDGF-BB expression was decreased in sMφ CM (data not shown). Coculture of SMC with macrophages also increased production of several proinflammatory cytokines by SMC. However, a similar level of induction with either sMφ or M0 macrophages was observed. M0 macrophages may acquire some features of the sMφ phenotype over time in coculture, thus masking differences between M0 and sMφ macrophages on certain aspects of SMC biology. More studies will be required to understand what sMφ-specific factors are capable of inducting enhanced SMC proliferation.
In summary, this study is one of the first to characterize the phenotype of macrophages present in intimal lesions associated with vascular injury and to successfully recapitulate such an in vivo phenotype using an in vitro system. Our results reveal a novel, physiologically relevant model system for studying macrophages that accumulate in the developing neointima. Importantly, these studies suggest that SMC-derived TGF-β1 may be a critical mediator of the macrophage vascular injury-specific polarization observed in vascular disease states such as atherosclerosis and restenosis. Furthermore, our cross talk studies begin to address the apparent paradox in that active TGF-β acts as a prodifferentiation factor for SMC, 38 yet in the setting of vascular injury, the net result of TGF-β antagonism is reduced neointima formation. 31, 33 Our results suggest that TGF-β signaling in maturing monocyte/macrophages results in an activated cell that subsequently secretes factors capable of further activating SMC on vascular injury.
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Macrophages have been shown to play an important role in promotion of neointima formation after vascular injury. These cells are highly plastic and respond to cues from the microenvironment by interacting with resident vascular cells. This study examines the role of vascular smooth muscle cells in modulating macrophage phenotype. Our data show that transforming growth factor-β produced by smooth muscle cell is critical for promoting a macrophage phenotype representative of that observed in injured vessels. These activated macrophages would be predicted to signal to the smooth muscle cell in vivo, resulting in a feed-forward promotion of neointima formation.
Significance
